Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Treace Medical Concepts, Inc. (TMCI)

NMS · Medical Devices

$4.01-0.07 (-1.72%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$260.1M
P/E (TTM)
EPS
$-0.96
Div Yield
52W Range
$1.17–$7.78
Beta
1.38

Company overview

Next earnings: 2026-08-07(10d)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Peers in Medical Devices

All in industry →

Recent press releases

April 2026

3 months agoARSHealthcare

TREACE MEDICAL CONCEPTS, INC. — ARS Filing

TMCITREACE MEDICAL CONCEPTS, INC.

# 🧾 What This Document Is This is TREACE MEDICAL CONCEPTS' **Annual Report to Shareholders (ARS)**. It's a comprehensive, one-stop document that gives shareholders and potential investors a full picture of the company's performance, strategy, risks, and financial health for the past year. Think of

Read summaryView on SEC EDGAR
3 months agoDEF 14AHealthcare

TREACE MEDICAL CONCEPTS, INC. — DEF 14A Filing

TMCITREACE MEDICAL CONCEPTS, INC.

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Treace Medical Concepts, Inc. (TMCI). It's an official invitation and information packet for the company's **2026 Annual Meeting of Stockholders**. Think of it as the agenda and briefing materials for a big company vot

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Treace Medical Concepts, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-03-31 · prior 2024-03-31
56,220 sh● NEW

People at Treace Medical Concepts, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$52.6M
NI -$15.9M
06/25
$47.4M
NI -$17.4M
09/25
$50.2M
NI -$16.3M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.26
Prior: $-0.28
Revenue sparkline